Abstract
Viruses belonging to the Flaviviridae family cause clinically significant diseases in humans and animals. This family includes three genera: Pestivirus [including bovine viral diarrhea virus (BVDV)], Flavivirus [including yellow fever virus (YFV), dengue virus, and West Nile virus (WNV)], and Hepacivirus [including hepatitis C virus (HCV)]. BVDV is responsible for major losses in cattle, causing a range of clinical manifestations, and is also a problematic contaminant in the laboratory. Noncytopathic BVDV infection can remain unnoticed and infect laboratory cell lines through its presence in contaminated bovine serum used in cell culture. BVDV is considered to be a valuable surrogate virus model for identifying and characterizing antiviral agents to be used against HCV. In some aspects of viral replication, BVDV is more advantageous than the currently used HCV replicon systems. In this review, we report the design, synthesis, and activity against BVDV of a series of compounds assayed until now.
Keywords: BVDV, HCV, Antiviral agents, Structure-activity relationship, Nucleosidic compounds, Non-nucleosidic compounds
Current Medicinal Chemistry
Title: What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?
Volume: 17 Issue: 26
Author(s): L.M. Finkielsztein, G.Y. Moltrasio, M.E. Caputto, E.F. Castro, L.V. Cavallaro and A.G. Moglioni
Affiliation:
Keywords: BVDV, HCV, Antiviral agents, Structure-activity relationship, Nucleosidic compounds, Non-nucleosidic compounds
Abstract: Viruses belonging to the Flaviviridae family cause clinically significant diseases in humans and animals. This family includes three genera: Pestivirus [including bovine viral diarrhea virus (BVDV)], Flavivirus [including yellow fever virus (YFV), dengue virus, and West Nile virus (WNV)], and Hepacivirus [including hepatitis C virus (HCV)]. BVDV is responsible for major losses in cattle, causing a range of clinical manifestations, and is also a problematic contaminant in the laboratory. Noncytopathic BVDV infection can remain unnoticed and infect laboratory cell lines through its presence in contaminated bovine serum used in cell culture. BVDV is considered to be a valuable surrogate virus model for identifying and characterizing antiviral agents to be used against HCV. In some aspects of viral replication, BVDV is more advantageous than the currently used HCV replicon systems. In this review, we report the design, synthesis, and activity against BVDV of a series of compounds assayed until now.
Export Options
About this article
Cite this article as:
Finkielsztein L.M., Moltrasio G.Y., Caputto M.E., Castro E.F., Cavallaro L.V. and Moglioni A.G., What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?, Current Medicinal Chemistry 2010; 17 (26) . https://dx.doi.org/10.2174/092986710792065036
DOI https://dx.doi.org/10.2174/092986710792065036 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fatty Acid Amide Hydrolase: A Potential Target for Next Generation Therapeutics
Current Pharmaceutical Design Retroviral Protein Transfer: Falling Apart to Make an Impact
Current Gene Therapy Sphingosine 1-Phosphate in Vascular Biology: Possible Therapeutic Strategies to Control Vascular Diseases
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Current Trends in the Management of Infected Necrotizing Pancreatitis
Infectious Disorders - Drug Targets The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Inflammation Biomarkers in Psychiatry
Current Psychiatry Research and Reviews Therapeutic Targets in Extracellular Protein Deposition Diseases
Current Medicinal Chemistry Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Synthesis, Biological and Computational Evaluation of Novel Oxindole Derivatives as Inhibitors of Src Family Kinases
Letters in Drug Design & Discovery Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes
Current Drug Metabolism Natural Anticoagulant Proteins in the Regulation of Autoimmunity: Potential Role of Protein S
Current Pharmaceutical Design The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry Thromboembolism with Immunomodulatory Agents in the Treatment of Multiple Myeloma
Cardiovascular & Hematological Agents in Medicinal Chemistry Effects of Mesenchymal Stromal Cells on Diabetic Cardiomyopathy
Current Pharmaceutical Design Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery